Pfizer Inc (PFE)

$24.90 -0.09 (-0.36%)
Market Cap 142.09B
Revenue (ttm) 63.63B
Net Income (ttm) 8.03B
EPS (ttm) N/A
PE Ratio 7.81
Forward PE 8.01
Profit Margin 12.62%
Debt to Equity Ratio 0.66
Volume 29,409,200
Avg Vol 67,806,570
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 10%
Beta 0.46
Analysts Sell
Price Target $27.95

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
taxplanr
taxplanr Jan. 1 at 2:38 AM
15 States looking to ban malignantRNA jabs in 2026 $BNTX $MRNA $PFE https://www.instagram.com/reel/DS8scQJDUsU/?igsh=MWs4OWo0NDg1bHQxaQ==
0 · Reply
apux
apux Dec. 31 at 11:51 PM
$VNDA -- This is going to be a really interesting ride this year. I still think it gets bought out but reading this really illustrates the total addressible market for their drug. $LLY $PFE $NVO The approval of NEREUS™ for the prevention of vomiting induced by motion validates its pharmacological profile and paves the way for further exploration of NK-1 antagonism in related vomit-inducing conditions. Vanda is advancing tradipitant in clinical development for gastroparesis, a chronic disorder characterized by delayed gastric emptying and persistent nausea/vomiting, as well as for the prevention of nausea and vomiting induced by GLP-1 receptor agonists—a common side effect impacting adherence in the rapidly growing obesity and diabetes treatment landscape. Vanda anticipates launching NEREUS™ for the prevention of vomiting induced by motion in the coming months and remains committed to expanding its therapeutic potential across indications driven by substance P-mediated pathways.
0 · Reply
N0Bounds
N0Bounds Dec. 31 at 11:38 PM
SNSE is Squeezing!!!! $FCX $PFE $CLSK $NUAI $BE K
1 · Reply
GoodTidings
GoodTidings Dec. 31 at 11:23 PM
$SLS Its clear there is a race of highest ownership of the stock... Who is behind it... Maybe BP? $MRK ? $PFE ? Or $MRK Hostile takeover? 🤔🤔🤔
0 · Reply
Jamessmithy
Jamessmithy Dec. 31 at 10:37 PM
$UUUU $ALAB $UBER $BE $PFE
0 · Reply
Mukulu2025
Mukulu2025 Dec. 31 at 9:57 PM
$PFE Time to shake off this inertia and move up in the new year in earnest. Added at close.
0 · Reply
Longbuy1
Longbuy1 Dec. 31 at 9:45 PM
$SLS $PFE $MRK $ABBV ABBV MRK PFE one of your companies is going to buy SLS for 10bil, shares will just converted. Float is 217M with all warrants exercised. Go buy some discounted shares. $GME you can meme SLS now market cap is about 500M. Easy 20-30 bagger that's the floor.
0 · Reply
N0Bounds
N0Bounds Dec. 31 at 9:42 PM
SNSE is the Next big Retail Squeeze!! $IVP $UBER $PFE $VRT $TTD F
0 · Reply
N0Bounds
N0Bounds Dec. 31 at 9:18 PM
$ALAB $IVP $PFE $UBER $APP pp
0 · Reply
Micheal_Pothead
Micheal_Pothead Dec. 31 at 8:25 PM
$PFE it’s just so blatant
1 · Reply
Latest News on PFE
3 ultra-high-yield stocks to consider for $300 of dividend income in 2026

Dec 31, 2025, 8:37 AM EST - 17 hours ago

3 ultra-high-yield stocks to consider for $300 of dividend income in 2026

AGNC PFLT

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

Dec 31, 2025, 6:08 AM EST - 20 hours ago

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

GSK LLY NVS SNY

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

Dec 26, 2025, 10:35 PM EST - 5 days ago

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

CVX KMB ABM ABT AMGN AVGO BCPC

Pfizer says patient dies after receiving hemophilia drug in trial

Dec 23, 2025, 11:24 AM EST - 8 days ago

Pfizer says patient dies after receiving hemophilia drug in trial

Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound

Dec 19, 2025, 11:45 AM EST - 12 days ago

Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound

Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 12 days ago

Trump to announce new drug-pricing deals later today

ABBV AMGN AZN BMY GILD LLY MRK

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

Dec 18, 2025, 10:00 AM EST - 13 days ago

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun

Dec 18, 2025, 6:58 AM EST - 13 days ago

Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun

AbbVie, several other pharma companies near MFN deal with Trump, sources say

Dec 17, 2025, 4:11 PM EST - 14 days ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AMGN AZN BMY LLY NVS

Pfizer Stock Can Sink More. Here Is How

Dec 17, 2025, 2:36 PM EST - 14 days ago

Pfizer Stock Can Sink More. Here Is How

Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back

Dec 17, 2025, 10:14 AM EST - 14 days ago

Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back

MRK

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Dec 17, 2025, 6:45 AM EST - 14 days ago

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript

Dec 16, 2025, 2:39 PM EST - 15 days ago

Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript

Pfizer falls on disappointing guidance

Dec 16, 2025, 12:33 PM EST - 15 days ago

Pfizer falls on disappointing guidance

Pfizer's modest 2026 outlook shows its big investments will take time to pay off

Dec 16, 2025, 10:12 AM EST - 15 days ago

Pfizer's modest 2026 outlook shows its big investments will take time to pay off

Here's why Pfizer is revising its revenue forecasts

Dec 16, 2025, 7:47 AM EST - 15 days ago

Here's why Pfizer is revising its revenue forecasts

Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales.

Dec 16, 2025, 7:25 AM EST - 15 days ago

Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales.

Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings

Dec 16, 2025, 7:16 AM EST - 15 days ago

Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings

Pfizer forecasts 2026 profit below expectations on lower COVID product sales

Dec 16, 2025, 6:54 AM EST - 15 days ago

Pfizer forecasts 2026 profit below expectations on lower COVID product sales

Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

Dec 16, 2025, 6:45 AM EST - 15 days ago

Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

Dec 15, 2025, 8:24 AM EST - 16 days ago

Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

ADPT

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Dec 15, 2025, 8:00 AM EST - 16 days ago

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

ADPT

Pfizer Declares First-Quarter 2026 Dividend

Dec 12, 2025, 12:00 PM EST - 19 days ago

Pfizer Declares First-Quarter 2026 Dividend

Dividend Harvesting Portfolio Week 249: $24,900 Allocated, $2,646.53 In Projected Dividends

Dec 12, 2025, 8:45 AM EST - 19 days ago

Dividend Harvesting Portfolio Week 249: $24,900 Allocated, $2,646.53 In Projected Dividends

AMLP MO MSTY OHI

Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial

Dec 12, 2025, 7:24 AM EST - 19 days ago

Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial

Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports

Dec 10, 2025, 11:38 AM EST - 21 days ago

Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

Dec 10, 2025, 8:15 AM EST - 21 days ago

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

Will Pfizer's YaoPharma deal deliver a powerful new oral obesity pill?

Dec 9, 2025, 3:30 PM EST - 22 days ago

Will Pfizer's YaoPharma deal deliver a powerful new oral obesity pill?

Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill

Dec 9, 2025, 11:14 AM EST - 22 days ago

Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill

Undisclosed Deaths in the Pfizer mRNA COVID-19 Vaccine Trial Discussed in the Journal of American Physicians and Surgeons

Dec 9, 2025, 10:59 AM EST - 22 days ago

Undisclosed Deaths in the Pfizer mRNA COVID-19 Vaccine Trial Discussed in the Journal of American Physicians and Surgeons

Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains

Dec 9, 2025, 10:45 AM EST - 22 days ago

Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains

Here's 12 Ideal 'Safer' December Dividend Dogs Of The S&P500

Dec 9, 2025, 10:15 AM EST - 22 days ago

Here's 12 Ideal 'Safer' December Dividend Dogs Of The S&P500

AES AMCR ARE CAG CPB D DOC

Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

Dec 9, 2025, 6:55 AM EST - 22 days ago

Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

Pfizer partners with YaoPharma for weight management treatment

Dec 9, 2025, 6:38 AM EST - 22 days ago

Pfizer partners with YaoPharma for weight management treatment

Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma

Dec 9, 2025, 6:30 AM EST - 22 days ago

Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

Dec 6, 2025, 5:15 PM EST - 25 days ago

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

Pfizer: The Market Is Still Wrong About It

Dec 5, 2025, 9:00 AM EST - 26 days ago

Pfizer: The Market Is Still Wrong About It

17 dividend-stock bargains from a value manager with a stellar track record

Dec 2, 2025, 12:11 PM EST - 4 weeks ago

17 dividend-stock bargains from a value manager with a stellar track record

BMY CIVI CMCSA CVS MOS MRK MTH

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

Dec 1, 2025, 3:50 PM EST - 4 weeks ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

BNTX MRNA NVAX

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Dec 1, 2025, 12:35 PM EST - 4 weeks ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

BNTX MRNA NVAX

Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance

Dec 1, 2025, 10:00 AM EST - 4 weeks ago

Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance

Pfizer: The Patent Cloud Is An Opportunity For Bargain Hunters

Nov 30, 2025, 6:13 AM EST - 4 weeks ago

Pfizer: The Patent Cloud Is An Opportunity For Bargain Hunters

Pfizer, Mastercard Among 24 Companies To Announce Annual Increases In December

Nov 29, 2025, 11:59 PM EST - 4 weeks ago

Pfizer, Mastercard Among 24 Companies To Announce Annual Increases In December

MA AVGO

8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills

Nov 28, 2025, 11:00 AM EST - 4 weeks ago

8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills

BBB BBY BMY CAG EQR KEY KIM

Final Trade: DAL, AXP, PFE, HMY

Nov 26, 2025, 6:20 PM EST - 5 weeks ago

Final Trade: DAL, AXP, PFE, HMY

AXP DAL HMY

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

Nov 26, 2025, 12:30 PM EST - 5 weeks ago

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

VALN

JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?

Nov 25, 2025, 5:20 AM EST - 5 weeks ago

JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?

JNJ

U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

Nov 21, 2025, 1:24 PM EST - 5 weeks ago

U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

Pfizer Crosses Below Key Moving Average Level

Nov 20, 2025, 4:05 PM EST - 5 weeks ago

Pfizer Crosses Below Key Moving Average Level

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

Nov 20, 2025, 11:17 AM EST - 5 weeks ago

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

AMGN BMY GILD IVV MRK SPY VOO

taxplanr
taxplanr Jan. 1 at 2:38 AM
15 States looking to ban malignantRNA jabs in 2026 $BNTX $MRNA $PFE https://www.instagram.com/reel/DS8scQJDUsU/?igsh=MWs4OWo0NDg1bHQxaQ==
0 · Reply
apux
apux Dec. 31 at 11:51 PM
$VNDA -- This is going to be a really interesting ride this year. I still think it gets bought out but reading this really illustrates the total addressible market for their drug. $LLY $PFE $NVO The approval of NEREUS™ for the prevention of vomiting induced by motion validates its pharmacological profile and paves the way for further exploration of NK-1 antagonism in related vomit-inducing conditions. Vanda is advancing tradipitant in clinical development for gastroparesis, a chronic disorder characterized by delayed gastric emptying and persistent nausea/vomiting, as well as for the prevention of nausea and vomiting induced by GLP-1 receptor agonists—a common side effect impacting adherence in the rapidly growing obesity and diabetes treatment landscape. Vanda anticipates launching NEREUS™ for the prevention of vomiting induced by motion in the coming months and remains committed to expanding its therapeutic potential across indications driven by substance P-mediated pathways.
0 · Reply
N0Bounds
N0Bounds Dec. 31 at 11:38 PM
SNSE is Squeezing!!!! $FCX $PFE $CLSK $NUAI $BE K
1 · Reply
GoodTidings
GoodTidings Dec. 31 at 11:23 PM
$SLS Its clear there is a race of highest ownership of the stock... Who is behind it... Maybe BP? $MRK ? $PFE ? Or $MRK Hostile takeover? 🤔🤔🤔
0 · Reply
Jamessmithy
Jamessmithy Dec. 31 at 10:37 PM
$UUUU $ALAB $UBER $BE $PFE
0 · Reply
Mukulu2025
Mukulu2025 Dec. 31 at 9:57 PM
$PFE Time to shake off this inertia and move up in the new year in earnest. Added at close.
0 · Reply
Longbuy1
Longbuy1 Dec. 31 at 9:45 PM
$SLS $PFE $MRK $ABBV ABBV MRK PFE one of your companies is going to buy SLS for 10bil, shares will just converted. Float is 217M with all warrants exercised. Go buy some discounted shares. $GME you can meme SLS now market cap is about 500M. Easy 20-30 bagger that's the floor.
0 · Reply
N0Bounds
N0Bounds Dec. 31 at 9:42 PM
SNSE is the Next big Retail Squeeze!! $IVP $UBER $PFE $VRT $TTD F
0 · Reply
N0Bounds
N0Bounds Dec. 31 at 9:18 PM
$ALAB $IVP $PFE $UBER $APP pp
0 · Reply
Micheal_Pothead
Micheal_Pothead Dec. 31 at 8:25 PM
$PFE it’s just so blatant
1 · Reply
barnml2006
barnml2006 Dec. 31 at 8:15 PM
$PFE Guess I'll have to DCA down soon.
0 · Reply
Makingmillions192
Makingmillions192 Dec. 31 at 8:04 PM
$LEXX Go give it a upvote if you can!! https://www.reddit.com/r/pennystocks/s/4YIcdKNkly $NVO $PFE $JAZZ
0 · Reply
MHM7700
MHM7700 Dec. 31 at 8:03 PM
$PFE 1/9 25c $0.23
0 · Reply
jhop123
jhop123 Dec. 31 at 7:39 PM
$PFE
0 · Reply
Longbuy1
Longbuy1 Dec. 31 at 7:13 PM
$SLS where only 41$ short of target value 45$. Question is when $PFE $ABBV $MRK buys us. $GME meme people can still jump in for a 20x bagger.
0 · Reply
Offender
Offender Dec. 31 at 5:45 PM
$PFE $25 all week 😂
0 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Dec. 31 at 5:35 PM
$PFE nice cup build intraday action
1 · Reply
sister
sister Dec. 31 at 5:32 PM
$MRNA $PFE can always get cheaper . . . $NVO too
2 · Reply
JustinTeel993
JustinTeel993 Dec. 31 at 5:23 PM
$TTE $PFE $BSX $UNP $RIO Nicely captured
0 · Reply
YoloAlfred
YoloAlfred Dec. 31 at 5:18 PM
$PFE $T & $PFE will both break $30 in 2026
0 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Dec. 31 at 4:43 PM
$PFE building positions under 25 will pay nicely in 2026 and beyond with Pfizer imo
0 · Reply
dom04
dom04 Dec. 31 at 4:42 PM
$PFE triple bottom rejection daily at 24,90$ if it hold, could be a strong bullish reversal toward 26$. Waiting this pm to buy this swing trade.
0 · Reply